RASL10A: A Non-Coding RNA Molecule with Potential as a Drug Target and Biomarker

Target Name: RASL10A

NCBI ID: G10633

RASL10A

RASL10A: A Non-Coding RNA Molecule with Potential as a Drug Target and Biomarker

RASL10A (Reverse Open Reading Frame 22) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. RASL10A is a key regulator of gene expression in many organisms, and its dysfunction has been implicated in the development and progression of numerous diseases. In this article, we will discuss the biology and potential therapeutic applications of RASL10A, as well as its potential as a drug target and biomarker.

Biography of RASL10A

RASL10A is a non-coding RNA molecule that was identified as a potential drug target and biomarker through various studies. It is a member of the Reverse Open Reading Frame (RORF) family, which is characterized by the presence of a reverse open reading frame, which is unique in that it is predominantly transcribed from the 5' to 3' end of the RNA molecule. RASL10A is approximately 210 nucleotides in length and has a unique 5'-end that contains a splicing enhancer and a putative RNA binding domain (RBD).

Expression and Function

RASL10A is a highly expressed gene in many organisms, including humans. It is expressed in a variety of tissues and cells, including brain, spinal cord, heart, and testes. RASL10A has been shown to play a role in the regulation of gene expression in many organisms, including cancer. For example, RASL10A has been shown to be involved in the regulation of stem cell proliferation and the development of cancer.

In addition to its role in stem cell biology, RASL10A has also been shown to be involved in the regulation of neurodegenerative diseases. For example, RASL10A has been shown to be involved in the regulation of neurotransmitter synthesis and release in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Potential Therapeutic Applications

RASL10A has the potential to be a drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the main reasons for its potential as a drug target is its unique structure and the diverse range of functions that it has been shown to play in many organisms.

For example, RASL10A has been shown to play a role in the regulation of cell signaling pathways, including the regulation of cell proliferation and the development of cancer. It is also involved in the regulation of stem cell biology, and has been shown to play a role in the development and progression of neurodegenerative diseases.

In addition to its potential as a drug target, RASL10A also has the potential to be a biomarker for a variety of diseases. Its expression has been shown to be involved in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it a promising candidate for use as a biomarker for a variety of diseases.

Conclusion

RASL10A is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and diverse range of functions make it a promising candidate for the development of new therapies for a variety of diseases. Further research is needed to fully understand the biology and potential therapeutic applications of RASL10A, as well as its potential as a drug target and biomarker.

Protein Name: RAS Like Family 10 Member A

Functions: Potent inhibitor of cellular proliferation

The "RASL10A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RASL10A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets